What are the key financial metrics reported for Q2 2025 and how do they compare to consensus estimates? | PPTA (Aug 14, 2025) | Candlesense

What are the key financial metrics reported for Q2 2025 and how do they compare to consensus estimates?

Key Q2 2025 metrics

  • Revenue: $45.2 million, vs. the Street’s consensus of $42.5 million (+6 %).
  • Adjusted EBITDA: $5.1 million, vs. the consensus of $4.8 million (+7 %).
  • Net loss: $12.3 million (or $0.28 loss per share), vs. the consensus expectation of a $10.8 million loss (‑$0.24 per share).
  • Cash & cash‑equivalents: $78 million at quarter‑end, up from $62 million a year ago, reflecting a $16 million operating‑cash generation beat.

Comparison to estimates & market reaction

Revenue and EBITDA came in ahead of expectations, underscoring the company’s ability to sustain production and cost‑control in its Boise operations. The loss miss is modest—largely driven by a one‑off non‑cash write‑down of $1.5 million—so the market has largely priced the beat in top‑line metrics rather than the slightly deeper loss. The net‑loss surprise widened the forward‑looking EPS guidance to a $0.30‑$0.34 loss range, still in line with the consensus‑midpoint of $0.31, limiting upside pressure.

Trading implications

  • Bullish case: The top‑line beat and stronger cash balance improve the balance‑sheet outlook, supporting a short‑term upside if the stock retests the $12‑$13 range (current price $11.8). A pull‑back to the $11.50‑$11.70 support zone could be a buying opportunity, especially with the sector in a neutral‑to‑bullish technical backdrop (MA‑20 above MA‑50, bullish MACD).
  • Bearish case: The net‑loss miss, albeit small, may prompt a re‑evaluation of the Q3 guidance. If the market perceives the loss as a sign of lingering cost‑headwinds, the stock could face resistance near $13, with a break below $11.50 opening the path to $10.5‑$10.0.

Actionable take‑away: With the earnings beat already baked into the price, a cautious long position on a dip to $11.50–$11.70 offers upside to $13‑$14 on a clean‑run of Q3, while keeping a stop just below $11.30 to guard against any widening of the loss narrative.